AC Immune (NASDAQ:ACIU) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of AC Immune (NASDAQ:ACIU) in a research report released on Wednesday morning,Benzinga reports. HC Wainwright currently has a $16.00 price objective on the stock. HC Wainwright also issued estimates for AC Immune’s Q4 2024 earnings at ($0.23) EPS, FY2024 earnings at ($0.62) EPS, FY2025 earnings at $0.41 EPS, FY2026 earnings at $0.75 EPS, FY2027 earnings at $1.36 EPS and FY2028 earnings at $1.95 EPS.

Separately, StockNews.com downgraded AC Immune from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st.

AC Immune Stock Down 2.1 %

Shares of AC Immune stock opened at $3.20 on Wednesday. AC Immune has a 12-month low of $2.25 and a 12-month high of $5.14. The firm has a market capitalization of $316.61 million, a PE ratio of -6.96 and a beta of 1.28. The stock’s fifty day moving average is $3.27 and its 200-day moving average is $3.46.

Institutional Trading of AC Immune

Several large investors have recently added to or reduced their stakes in ACIU. Silverberg Bernstein Capital Management LLC acquired a new stake in shares of AC Immune in the second quarter worth $40,000. Lazard Asset Management LLC acquired a new position in AC Immune during the first quarter valued at $30,000. BNP Paribas Financial Markets lifted its stake in AC Immune by 315.6% in the 1st quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock worth $33,000 after acquiring an additional 8,423 shares in the last quarter. Vanguard Capital Wealth Advisors acquired a new stake in AC Immune during the 2nd quarter worth about $56,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in AC Immune by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock valued at $72,000 after acquiring an additional 7,400 shares in the last quarter. 51.36% of the stock is owned by institutional investors and hedge funds.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.